Shire Shrugs Off Lifitegrast CRL; Launch Expected In 2016
This article was originally published in The Pink Sheet Daily
With top-line data from additional Phase III expected this quarter, Shire plans to refile lifitegrast for approval in dry-eye syndrome in early 2016, making approval and launch by the third quarter next-year feasible.
You may also be interested in...
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.